On January 6, according to Gelonghui, the Traditional Chinese Medicine sector in the A-share market rose against the trend. Among them, Datang Pharmaceutical rose nearly 19%, Shanghai Kaibao Pharmaceutical rose over 16%, Xiangxue Pharmaceutical rose over 14%, Tailing Pharmaceutical, Shijiazhuang Yiling Pharmaceutical, Hainan Huluwa Pharmaceutical Group, and Guangdong Zhongsheng Pharmaceutical all reached a 10% limit up. Shanghai Shenqi Pharmaceutical Investment Management rose 9%, Jinghua Pharmaceutical Group, Tianjin Chase Sun Pharmaceutical, and Jiangxi Wannianqing Cement rose over 8%. Guizhou Sanli Pharmaceutical Co.,Ltd., Bio Valley, and Guizhou Xinbang Pharmaceutical rose over 7%. Shandong Wohua Pharmaceutical, Sunflower Pharmaceutical Group rose over 6%, Zhejiang Xinguang Pharmaceutical, Oukan Pharmaceutical, Gansu Longshenrongfa Pharmaceutical Industry, and Guilin Sanjin Pharmaceutical rose over 5%. Guiyang Xintian Pharmaceutical, Zhejiang Wecome Pharmaceutical, Chongqing Taiji Industry, and Hubei Jumpcan Pharmaceutical rose over 4%. Lanzhou Foci Pharmaceutical, Enwei Pharmaceutical, Hunan Hansen Pharmaceutical, Jiangsu Kanion Pharmaceutical, KPC Pharmaceuticals, Inc., Yabao Pharmaceutical Group, Guizhou Yibai Pharmaceutical, and Jilin Jian Yisheng Pharmaceutical rose over 3%. In the news, the General Office of the State Council recently issued the "Opinions on Comprehensively Deepening the Reform of Drug and Medical Instrument Supervision to Promote High-Quality Development of the Pharmaceutical Industry". It calls for increasing support for research and innovation in Traditional Chinese Medicine. The improvement of the review evidence system for Traditional Chinese Medicine characteristic evaluation, which combines Traditional Chinese Medicine theory, human experience, and clinical trials, is required. A mechanism for standardizing the collection and organization of human experience data by medical institutions should be established. A regulatory system that is suited to the characteristics of Traditional Chinese Medicine should be improved. Active support is given for the transformation of prescriptions by renowned old Traditional Chinese Medicine practitioners and Traditional Chinese Medicine preparations in medical institutions into new drugs. The use of new technologies, new processes, and new dosage forms that fit product characteristics to improve marketed Traditional Chinese Medicine varieties is encouraged. (Gelonghui)